文献速递肝病消化道出血

高目标平均动脉压与低目标平均动脉压用于肝硬化脓毒性休克患者的随机对照试验(TARGET-C)

A randomised-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock.
PubMed 文献 · J Hepatol · 2023-04-23

TARGET-C 试验将 150 例肝硬化脓毒性休克患者 1:1 随机分为高目标平均动脉压(MAP)组(80-85 mmHg,75 例)与低目标 MAP 组(60-65 mmHg,75 例),主要终点 28 天死亡率在两组间无差异(65% vs 56%,p=0.54)。高目标 MAP 组透析中低血压发生率更低(12% vs 48%,p<0.001),但需中断方案的 adverse events 更多(24% vs 11%,p=0.031)。

要点

  • 高目标 MAP 未改善肝硬化脓毒性休克患者 28 天死亡率(65% vs 56%,p=0.54)。
  • 高目标 MAP 组透析中低血压发生率更低(12% vs 48%,p<0.001)。
  • 高目标 MAP 组需中断方案的 adverse events 更多(24% vs 11%,p=0.031)。

核心结论

  • 较高的 MAP 策略未给肝硬化脓毒性休克患者带来生存获益,但改善透析耐受性、乳酸清除和肾脏恢复。
  • 较高的 adverse events 表明需要更好的工具来评估目标微循环压力。

研究设计与样本

  • 开放标签、1:1 随机对照试验,纳入 150 例肝硬化脓毒性休克患者,高目标 MAP 组 75 例、低目标 MAP 组 75 例。
  • 主要终点为 28 天死亡率;次要终点包括休克逆转、第 5 天急性肾损伤(AKI)、透析中低血压(IDH)发生率和 adverse events。
  • 对部分患者分析了内皮标志物。

主要发现

  • 意向性治疗分析:28 天死亡率高目标 MAP 组 65% vs 低目标 MAP 组 56%(p=0.54),休克逆转 47% vs 53%(p=0.41),AKI 发生 45% vs 31%(p=0.06),均无差异。
  • 高目标 MAP 组 IDH 发生率更低(12% vs 48%,p<0.001),需中断方案的 adverse events 更多(24% vs 11%,p=0.031)。
  • 符合方案分析(低目标 MAP 组 67 例、高目标 MAP 组 57 例):高目标 MAP 组 AKI 逆转更高(53% vs 31%,p=0.02),IDH 发生率更低(4% vs 53%,p<0.001)。
  • 内皮修复标志物 ADAMTS 在高目标 MAP 组更高(2.11 ± 1.13 vs 1.15 ± 0.48,p=0.002),angiopoietin-2 也更高(74.08 ± 53.00 vs 41.80 ± 15.95,p=0.016)。

临床怎么用

  • 作者认为,对肝硬化脓毒性休克患者可考虑采用较高目标 MAP 策略并密切监测 adverse events。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A high mean arterial pressure (MAP) target has been associated with improved renal outcomes in patients with cirrhosis, though it has not been studied in critically ill patients with cirrhosis and septic shock (CICs). We compared the efficacy of a high (80-85 mmHg; H-MAP) vs. low (60-65; L-MAP) target MAP strategy in improving 28-day mortality in CICs. METHODS: We performed open-label 1:1 randomisation of 150 CICs (H-MAP 75; L-MAP 75). The primary endpoint was 28-day mortality and secondary endpoints included reversal of shock, acute kidney injury (AKI) at day 5, the incidence of intradialytic hypotension (IDH), and adverse events. Endothelial markers were analysed in a subset of patients. RESULTS: The baseline characteristics were comparable. On intention-to-treat analysis, 28-day mortality (65% vs. 56%; p = 0.54), reversal of shock (47% vs. 53%; p = 0.41) and AKI development (45% vs. 31%;p = 0.06) were not different between the H-MAP and L-MAP groups, respectively. A lower incidence of IDH (12% vs. 48%; p <0.001) and higher adverse events necessitating protocol discontinuation (24% vs. 11%; p = 0.031) were noted in the H-MAP group. On per-protocol analysis (L-MAP 67; H-MAP 57), a significantly higher reversal of AKI (53% vs. 31%; p = 0.02) and a lower incidence of IDH (4% vs. 53%; p <0.001) were observed in the H-MAP group. Endothelial repair markers such as ADAMTS (2.11 ± 1.13 vs. 1.15 ± 0.48; p = 0.002) and angiopoietin-2 (74.08 ± 53.00 vs. 41.80 ± 15.95; p = 0.016) were higher in the H-MAP group. CONCLUSIONS: A higher MAP strategy does not confer a survival benefit in CICs, but improves tolerance to dialysis, lactate clearance and renal recovery. Higher adverse events indicate the need for better tools to evaluate target microcirculation pressures in CICs. IMPACT AND IMPLICATIONS: Maintaining an appropriate organ perfusion pressure during sepsis is the ultimate goal of haemodynamic management. A higher mean arterial pressure (MAP) improves renal outcomes in patients with hepatorenal syndrome. Patients with cirrhosis and septic shock have severe circulatory disturbances, low MAP, and poor tissue perfusion. In these patients, targeting higher MAP vs. lower MAP does not confer any survival benefit but is associated with more adverse events. A higher target strategy was associated with better tolerance and lesser episodes of hypotension on dialysis. Patients who could achieve the higher target MAP, without the development of adverse events, had improved renal outcomes and better lactate clearance. Higher MAP was also associated with improvements in markers of endothelial function. A higher target MAP strategy, with close monitoring of adverse events, may be recommended for patients with cirrhosis and septic shock. CLINICAL TRIAL NUMBER: NCT03145168.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Maiwall R, Rao Pasupuleti SS, Hidam AK, et al. A randomised-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock. J Hepatol. 2023. PMID: 37088310. doi:10.1016/j.jhep.2023.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。